AntiViral Research Center In the Department of Medicine
You are here: Home Participate Current Studies

Current Studies

The AVRC is currently researching:


Hepatitis C (HCV)

  • An interferon-free therapy for chronic HCV-1 & HIV co-infected individuals (C-ASCENT)



  • Whether a daily dose of a statin medication (i.e. pitavastatin) lowers the risk of heart-related disease among people living with HIV (REPRIEVE).
  • A specialized HIV test that can detect HIV as early as one week after exposure to the virus (The Early Test).
  • One strategy on the pathway to possibly curing HIV by activating hidden HIV in the body using an investigational oral toll-like receptor 7 (TLR7) agonist (Kick and Kill).
  • Whether adding maraviroc and/or dolutegravir to a stable ARV regimen will improve one's ability to concentrate, remember, solve problems and make decisions (HAND).
  • The effects of ruxolitinib on inflammation in HIV.
  • Perturbing the HIV reservoir with immune stimulation, using the flu and pneumonia vaccines (Perturb).
  • What happens and the safety of when people pause, or temporarily stop taking, ART, and to collect blood samples from these people at frequent intervals (A5345).
  • The safety, tolerability, pharmacokinetics and antiviral efficacy of the PGT121 monoclonal antibody for HIV prevention and therapy (starting in June/July 2017).


Pre-Exposure Prophylaxis (PrEP)

  • HIV prevention methods with HIV-negative cisgender women using pre-exposure prophylaxis (PrEP) and text messaging (AEGiS).
  • A novel wireless ingestible sensor system for measurement of medication adherence in HIV prevention for men and women.
  • The safety and efficacy of Descovy (F/TAF) for PrEP in men and transgender women who have sex with men and are at risk of HIV-1 infection (DISCOVER).
  • HIV prevention methods with HIV-negative transgender and gender non-conforming persons using pre-exposure prophylaxis (PrEP) and text messaging (starting in June 2017).


Women's Reproductive Health (for HIV-negative individuals)

  • An investigational drug called Lactin-V that may prevent recurrent bacterial vaginosis or BV (LACTIN-V).


To learn more about these and other current clinical trials, please call us at (619) 543-8080 and ask for the Screening Coordinator.

Page 'Breadcrumb' Navigation:

You are here: Home Participate Current Studies

External Resources: